Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Diovan Becomes Best-Selling Drug in April-June: IMS Japan
September 6, 2010
- Homeopathy Has No Scientific Grounds: SCJ
September 6, 2010
- Doctors Hope for Entry of Major Pharmas into Generics Market: Survey
September 6, 2010
- IBD Market to Grow to US$5.6 Bil. in 2019: Datamonitor
September 6, 2010
- Kyowa Kirin Withdraws Application for KW-2246
September 6, 2010
- Questionnaires on Use of Generics to Be Reconsidered
September 6, 2010
- JPMA Calls For Reduction in Effective Corporate Tax Rate to Int'l Standard
September 6, 2010
- Average PMDA Staff Member Earns ¥7,223,000 per Year
September 6, 2010
- Kyowa Kirin Launches Nesp Inj. Plastic Syringe
September 6, 2010
- 3 Switch OTC Drugs Recommended for Approval
September 6, 2010
- Ain Pharmaciez to Strengthen Tie with 7&i HD
September 6, 2010
- General Consumers Show Great Interest in Switch OTC Drugs: JSMI Survey
September 6, 2010
- CDFS Withholds Recommendation of Approval for Liovel
September 6, 2010
- Sales of Class 1 OTC Drugs Up for the 1st Time since PAL Amendment: JSMI
September 6, 2010
- Treakisym from SymBio Recommended for Approval
September 6, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…